FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Real-time Boerse Frankfurt Warrants 13:23:02 26/06/2024 BST | ||
| 12.03 EUR | +1.35% |
|
| Current month | +19.42% | ||
| 1 month | +5.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 12.03 | +1.35% |
| 25/06/24 | 11.87 | +3.31% |
| 24/06/24 | 11.49 | -2.96% |
| 21/06/24 | 11.84 | +7.54% |
| 20/06/24 | 11.01 | +5.06% |
Real-time Boerse Frankfurt Warrants
Last update June 26, 2024 at 01:23 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SW9XKY |
| ISIN | DE000SW9XKY3 |
| Date issued | 06/05/2024 |
| Strike | 12,139 p |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.78 € |
|---|---|
| Lowest since issue | 8.13 € |
| Spread | 0.15 € |
| Spread % | 1.22% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
159
USD
Average target price
174.4
USD
Spread / Average Target
+9.66%
- Stock Market
- Certificates
- Certificat
